Actively Recruiting
The Role of 18F-FDG and 68Ga-FAPI PET/CT in Diagnosing and Evaluating Advanced Colorectal Cancer with Peritoneal Metastasis
Led by Ruijin Hospital · Updated on 2025-01-22
30
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of two types of PET/CT scans, 18F-FDG and 68Ga-FAPI, to assess how well conversion therapy works and to predict outcomes in people with advanced colorectal cancer that has spread to the peritoneum, with or without other metastases. The study focuses on comparing imaging results with pathological or clinical assessments to better understand the diagnostic and treatment evaluation value of these imaging methods. Participants will have both 18F-FDG and 68Ga-FAPI PET/CT scans at the start of the study and again after three months of conversion therapy. Their imaging results will be compared to clinical or tissue-based assessments to determine how accurately these scans evaluate treatment response. The study collects basic personal and medical information, and tracks imaging data over this three-month period. During the study, participants will provide medical history and contact details, and undergo imaging tests at two time points: baseline and after three months. Researchers will monitor diagnostic accuracy, standardized uptake values, and target-to-background ratios from the scans. The study ensures participants meet specific health criteria and follows them through the therapy period to measure imaging outcomes and prognosis for up to three months.
CONDITIONS
Official Title
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed colorectal cancer with clinical or imaging suspicion of peritoneal metastasis, with or without other distant metastases
- Voluntary enrollment with signed informed consent
- Age 18 years or older
- Expected life expectancy of at least 3 months
- Adequate organ and bone marrow function
- Willingness to follow the study protocol and attend follow-up visits
You will not qualify if you...
- Pregnant or breastfeeding women
- History of other malignant diseases within the last 5 years, except cured skin cancer and carcinoma in situ of cervix
- Severe mental illness, uncontrolled epilepsy, or central nervous system disease
- Current or past interstitial pneumonitis or lung disease requiring hormonal therapy, or other lung conditions that could affect immune-related pulmonary toxicity management
- Active tuberculosis or severe pulmonary impairment seen on CT scan
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
J
Jiajia Hu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here